CALGARY, June 12 /PRNewswire-FirstCall/ – Oncolytics Biotech Inc. (TSX:
ONC, NASDAQ: ONCY), announced today that Dr. Brad Thompson, President and CEO
of Oncolytics, will participate in two separate presentations at the BIO 2008
Dr. Thompson is scheduled to provide a corporate overview of the Company
on Tuesday, June 17th at 3:30 p.m. PT at the BIO Business Forum.
On Wednesday, June 18th at 4:00 p.m. PT, Dr. Thompson is also scheduled to
participate as an invited speaker as part of a panel discussion entitled
“Canada: Your Global Partner for Cancer Research Innovation.”
The Conference, which is expected to draw approximately 20,000 attendees,
will be held at the San Diego Convention Center June 17th to June 20th, 2008.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics’
clinical program includes a variety of Phase I/II and Phase II human trials
using REOLYSIN(R), its proprietary formulation of the human reovirus, alone
and in combination with radiation or chemotherapy. For further information
about Oncolytics, please visit www.oncolyticsbiotech.com
The presentation times are subject to change. This release and the
presentations related thereto contain forward-looking statements which involve
known and unknown risks, delays, uncertainties and other factors not under the
Company’s control and which may cause actual results, performance or
achievements of the Company to be materially different from the results,
performance or expectations implied by these forward-looking statements. Such
risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as
a cancer treatment, the success and timely completion of clinical studies and
trials, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and general
changes to the economic environment. Investors should consult the Company’s
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing undue
reliance on forward- looking statements. The Company does not undertake to
update these forward-looking statements.
SOURCE Oncolytics Biotech Inc.
Released June 12, 2008